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Proteases are now considered not only to be enzymes that conduct hydrolysis of
peptide bonds linking amino acids, but also signaling molecules that play an
important role in homeostatic regulation in mammals and numerous pathological
conditions.1,2 In the skin, three families of proteases have been found in the stratum
corneum (SC), including the epidermal specific serine proteases, kallikrein 5 (SC
tryptic enzyme, SCTE) and kallikrein 7 (SC chymotryptic enzyme, SCCE), as
well as cysteine proteases, including cathepsin C, L, and V (SC thiol protease),
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Proteases in the skin are essential to epidermal permeability barrier homeostasis.
In addition to their direct proteolytic effects, certain proteases signal to cells by
activating protease-activated receptors (PARs), the G-protein-coupled receptors.
The expression of functional PAR-2 on human skin and its role in inflammation,
pruritus, and skin barrier homeostasis have been demonstrated. Atopic dermatitis
(AD) is a multifactorial inflammatory skin disease characterized by genetic barrier
defects and allergic inflammation, which is sustained by gene-environmental
interactions. Recent studies have revealed aberrant expression and activation of
serine proteases and PAR-2 in the lesional skin of AD patients. The imbalance
between proteases and protease inhibitors associated with genetic defects in the
protease/protease inhibitor encoding genes, increase in skin surface pH, and
exposure to proteolytically active allergens contribute to this aberrant protease/
PAR-2 signaling in AD. The increased protease activity in AD leads to abnormal
desquamation, degradation of lipid-processing enzymes and antimicrobial
peptides, and activation of primary cytokines, thereby leading to permeability
barrier dysfunction, inflammation, and defects in the antimicrobial barrier.
Moreover, up-regulated proteases stimulate PAR-2 in lesional skin of AD and lead
to the production of cytokines and chemokines involved in inflammation and
immune responses, itching sensation, and sustained epidermal barrier perturbation
with easier allergen penetration. In addition, PAR-2 is an important sensor for
exogenous danger molecules, such as exogenous proteases from various allergens,
and plays an important role in AD pathogenesis. Together, these findings suggest
that protease activity or PAR-2 may be a future target for therapeutic intervention
for the treatment of AD.
Key Words: Atopic dermatitis, protease, protease-activated receptor-2 (PAR-2)
Received: August 17, 2010
Corresponding author: Dr. Seung Hun Lee,
Department of Dermatology,
Yonsei University College of Medicine, 
Gangnam Severance Hospital,
712 Eonju-ro, Gangnam-gu,
Seoul 135-720, Korea.
Tel: 82-2-2019-3361, Fax: 82-2-3463-6136
E-mail:  ydshderm@yuhs.ac
∙The authors have no financial conflicts of
interest.
© Copyright:
Yonsei University College of Medicine 2010
This is an Open Access article distributed under the
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.
INTRODUCTION
and at least one aspartate protease, cathepsin D.3-7 These
proteases are tightly regulated by specific protease inhibi-
tors and mediate various cellular responses in the skin,
such as inflammation and immune responses, host defense,
chemotaxis, cytokine expression, vascular function, tissue
repair, and apoptosis.8 In addition to endogenous proteases,
exogenous proteases from allergens such as house dust
mites, cockroaches, certain bacteria, and fungi can also
signal the epidermis. A number of biological activities of
proteases are mediated, at least in part, by the activation of
its receptors, protease-activated receptors (PARs).9 Recent
works have indicated that PAR-2, as a sensor for endoge-
nous as well as exogenous proteases, plays numerous
physiological and pathophysiological roles in the skin.8,10 In
addition, there is increasing evidence that protease and
PAR-2 play an important role in the maintenance of epi-
dermal permeability barrier homeostasis.7,11,12 Moreover,
abnormal expression or activity of serine proteases and
PAR-2 has been associated with several inflammatory skin
disorders involving barrier abnormalities, including atopic
dermatitis, netherton syndrome (NS), psoriasis, and
peeling skin syndrome.13-18 In this review, we will discuss
the role of protease/PAR-2 signaling in epidermal permea-
bility barrier homeostasis, as well as its contribution to the
pathogenesis of atopic dermatitis (AD). 
Human tissue kallikreins (KLKs) are the largest family of
trypsin- or chymotrypsin-like secreted serine proteases.13
Eight KLKs, including KLK5, -6, -7, -8, -10, -11, -13, and
-14 are known to be expressed in the epidermis and skin
appendages, such as sebaceous gland.19 Among these, only
KLK7 exhibits chymotrypsin-like substrate specificity; the
other KLKs exhibit trypsin-like serine proteases. It is well
known that KLK5 and KLK7 are the major active KLKs
in the SC, regulating the desquamation process through
corneodesmosomal cleavage and lipid barrier formation by
degrading lipid processing enzymes.19-21 In addition, KLK5
and KLK7 have been shown to control the enzymatic
processing of cathelicidin, thereby affecting its antimicro-
bial activity and inflammatory responses.22 KLK14 has also
been detected in its active form in the SC and is thought to
be a candidate protease involved in the process of desqua-
mation, however, its precise role has not been elucidat-
ed.23,24 KLK5 and KLK7 are stored in the form of pro-
enzyme in the lamellar bodies (LBs) along with a substrate
of KLK7, corneodesmosin and their inhibitor, lymphoe-
pithelial Kazal-type-related inhibitor (LEKTI).25 Upon
release into the stratum granulosum (SG)-SC interface,
these pro-KLK zymogens are activated through a KLK
proteolytic activation cascade.26 KLK5 can be activated by
itself or by KLK14 and then activate several other pro-
KLKs; therefore KLK5 is thought to be the key protease
for the initiation of the KLK cascade.24 Significantly, KLK5
and KLK14 are known to activate PAR-2, thereby modulat-
ing epidermal permeability barrier homeostasis, immune
and inflammatory responses, skin pigmentation, itching
sensations, as well as tumor surveillance.10,27 KLK8 has
been reported to be localized in the LBs with KLK5, KLK7
and their inhibitors and secreted in the SG-SC interface,
regulating desquamation and epidermal proliferation.28,29
Recent studies have investigated factors regulating the
expression of KLKs in the skin and reported that epider-
mal calcium ions, vitamin D3, and retinoic acid indepen-
dently regulate the expression of KLK5 and KLK7 in
normal human epidermal keratinocytes.30 An increase in
extracellular calcium induced KLK5 and KLK7 expres-
sion with induction of differentiation markers, suggesting
that the expression of KLKs is induced during epidermal
differentiation. In contrast, both 9-cis retinoic acid and 13-
cis retinoic acid increased KLK5 and KLK7 expression,
independently of keratinocyte differentiation. 1,25 (OH)2
vitamin D3, which is well known to induce cathelicidin
expression, was also demonstrated to stimulate the expres-
sion of KLK5 and KLK7, which are co-localized with
cathelicidin. 
In addition to KLKs, the two transmembrane serine
protease, matriptase (MT-SP1) and prostasin have been
identified in the uppermost epidermal layers and postulated
to be involved in epidermal barrier formation and SC hydra-
tion via epithelial sodium channel-induced intracellular
calcium influx and consequent activation of calcium-
dependent proteases and transglutaminases (TGMs).31
Moreover, the observation that mice deleted for matriptase
showed impaired desquamation suggests that matriptase is
also involved in the process of desquamation.32
A number of serine protease inhibitors are present in the
skin, and regulate proteolytic activity in order to prevent
excessive serine protease cascade, while also maintaining
permeability barrier homeostasis. Among several serine
protease inhibitors observed in the SC, such as secretory
leucocyte protease inhibitor (SLPI), elafin skin-dericed
antileukoproteinase (SKALP), and plasminogen activator
inhibitor type 2, which are normally cross-linked to the
cornified envelope, LEKTI-1, a secreted serine protease in-
hibitor, is thought to be the major player in the SC. LEKTI
is encoded by SPINK5 (serine protease inhibitor Kazal-
type 5) and its multidomains exhibit diverse inhibitory
effects toward trypsin, plasmin, subtilisin A, cathepsin G,
and human neutrophil elastase.33 In addition, previous in
vitro studies demonstrated that LEKTI fragments could
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inhibit KLK5, -6, -7, -13, and -14.31 LEKTI-1 is stored in
specific intracellular LB cargoes, separated from the
KLKs, until it is secreted and released into the SC-SG
junction to colocalize with KLK5 and KLK7 and inhibit
their activity. The interaction strength between LEKTI-1
and KLKs is regulated by the SC pH gradient, with its
highest inhibitory capacity at a neutral pH and decreased
activity in an acidic pH environment, such as in the
superficial SC layer. This implies that a normal SC pH
gradient regulates the controlled release of active KLKs in
the superficial SC layer and prevents premature desqua-
mation in the deep SC layer, where the pH is neutral.34
These findings support the fact that AD, characterized by
altered skin surface pH, and NS, characterized by geneti-
cally defective LEKTI, display similar phenotypic features,
including premature and excessive desquamation. Recen-
tly, LEKTI-2, the product of SPINK9, has been identified to
be focally localized at the SG and SC at palmar and plantar
sites in close proximity to KLK5.35 It was found that
recombinant LEKTI-2 inhibited KLK5 but not KLK7 and
-14, suggesting that LEKTI-2 contributes to the regulation
of the desquamation process by inhibiting KLK5 pro-
teolytic activity. Other serine protease inhibitors and their
roles are summarized in Table 1.36-38
PAR is a G-protein coupled receptor, characterized by a
unique mechanism of self-activation following specific
proteolytic cleavage of their extracellular domains.39 Until
now, four PAR members have been identified. PAR-1, -3,
and -4 are known to be activated by thrombin, and thereby
involved in homeostasis and thrombosis, whereas PAR-2
is activated by trypsin-like serine proteases, but not by
thrombin.10,40 PAR-2 is known to be widely distributed
throughout the mammalian body. In the skin, PAR-2 is
abundantly expressed by almost all cell types, especially
by keratinocytes. In addition, endothelial cells, fibroblasts,
sensory neurons, and inflammatory cells such as mast
cells, T lymphocytes, eosinophils, neutrophils, monocytes,
macrophages, and dendritic cells are also reported to ex-
press functional PAR-2.10,40 Previous studies demonstrated
that PAR-2 was expressed in the suprabasal layers of both
human and murine epidermis, and that this expression was
most prominent in the granular layer, implying that PAR-2
expression might depend on the state of epidermal differ-
entiation.7,40 As opposed to normal skin, the lesional skin of
atopic dermatitis has been shown to express high levels of
PAR-2 also in the lower epidermal layers.21,40,41 PAR-2 as
well as KLK14 has been shown to be widely distributed in
lesional skin in rosacea, another inflammatory skin
disease.21 Taken together, this evidence suggests that PAR-
2 expression may be induced by cutaneous inflammation.
In addition, PAR-2 expression has been reported to be re-
gulated by ultraviolet irradiation and involved in melano-
some transfer.42 
Various endogenous serine proteases including trypsin,
mast cell derived tryptase, KLK5, -6, and, -14, matriptase-
1 [membrane-type serine protease-1 (MT-SP1)], human
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Table 1. Serine Proteases and Their Inhibitor in Skin 
Serine protease inhibitor Genes Target proteases Function or disease 
association
Lymphoepithelial Kazal- Serine protease inhibitor Trypsin, plasmin, subtilisin A, Netherton syndrome
type-related inhibitor-1 Kazal-type5 (SPINK5) cathepsin G, human neutrophil
(LEKTI-1) elastase, KLK5, -6, -7, -13, -14
LEKTI-2 SPINK 9 KLK5 Hyperkeratotic hand and 
foot eczema
Alpha-2 macroglobulin- A2ML1 KLK7, papain, subtilisin Regulation of 
like 1 (α2ML1)37 desquamation by 
limiting the 
bioavailability
of KLK7 in the SC
Secretory leukocyte protease Trappin gene family Neutrophil serine proteases Antimicrobial defense
inhibitor (SLPI)/Elafin in the skin
Hepatocyte growth factor Serine protease inhibitor Matriptase Matriptase transport 
activator inhibitor 1 Kunitz type 1 (SPINT1) (probably prostatin) and activation
(HAI-1)38,39 gene
SC, stratum corneum.
PAR-2 IN SKIN 
airway trypsin-like protease (HAT), cathepsin G, and factor
Xa have been demonstrated to activate PAR-2. In addition,
some kinds of pathogenic organisms with proteolytic acti-
vity such as house dust mites, cockroaches, pollens, molds
or bacteria may also be exogenous activators of PAR-2.
Upon activation, PAR-2, which is mainly localized to lipid
raft domains under basal status, is known to be endocytosed
and degraded.7,43 As a G-protein coupled receptor, PAR-2 is
known to have a common signaling pathway, including the
activation of phospholipase C, which results in the forma-
tion of ionsitol triphosphate and diacylglycerol, followed
by calcium mobilization.39 In vitro, PAR-2 activation by
PAR-2 agonist peptide has been demonstrated to provoke
transient intracellular calcium mobilization in primary kera-
tinocytes, suggesting that PAR-2 could regulate the proli-
feration and differentiation of keratinocytes.44,45 The precise
role of PAR-2 in epidermal barrier homeostasis is discuss-
ed below. 
KLKs and their inhibitors are co-localized in the LBs and
secreted to the SG-SC junction. The enzyme activity of
various proteases in the skin and the inhibitory activity of
protease inhibitors are regulated by the SC pH gradient.
These findings imply that proteases play an important role
in epidermal permeability barrier homeostasis, and recent
studies have further shown the importance of proteases and
PAR-2 signaling in the barrier function of the skin. Pro-
teases exert various cellular responses, some of which may
be, in part, mediated via activation of PAR-2.
Non-PAR-2-mediated function
Filaggrin processing
Filaggrin aggregates keratin intermediate filaments to form
the cornified cell envelope, thereby providing the structural
support and mechanically resilient skin barrier. In addition,
these polypeptides are degraded into natural moisturizing
factors (NMF), and contribute to water retention within the
SC layers, helping to maintain skin hydration.46,47 A num-
ber of proteases, including PEP-1, µ-calpain, furin, prosta-
tin, matriptase, and caspase-14, elastase2 (ELA2), have
been demonstrated to be involved in the proteolytic pro-
cessing of filaggrin and profilaggrin, which leads to epi-
dermal differentiation, barrier formation and hydration.32,48-52
Recently, the two membrane-bound serine proteases matri-
ptase and prostasin have been reported to be involved in
the processing of profilaggrin by activating the epithelial
sodium channel (ENaC) which causes a calcium influx
through a voltage-gated calcium channel, thereby inducing
the activation of calcium-dependent proteases.31 Matriptase,
or MT-SP1 is a type II trans-membrane serine protease and
is now considered to be an essential component of the pro-
filaggrin-processing pathway, in accordance with the
observation that neonate Matriptase/MT-SP1-deficient
skin displayed a loss of mature filaggrin monomer.32 Matri-
ptase is also known to be co-localized with another mem-
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Fig. 1. Role of serine proteases in the epidermal permeability barrier homeostasis. aSMase, acid sphingomyelinase; β-GlcCer’ase, β-
glucocerebrosidase; CDSN, corneodesmosin; DSC, desmocollin; DSG, desmoglein; KLK, kallikrein; LB, lamellar body; PAR-2, protease-activated
receptor-2; SC, stratum corneum. 
PROTEASE/PAR-2 AND 
EPIDERMAL BARRIER 
brane-bound serine protease, prostatin (CAP1/PRSS8),
and could activate prostatin in vitro, resulting in the initia-
tion of a proteolytic cascade toward ENaC activation.53
Desquamation
Desquamation involves the enzymatic process of degrada-
tion of corneodesmosomal proteins including corneodes-
mosin (CDSN), desmoglein 1 (DSG1), and desmocollin 1
(DSC1). It is well known that KLKs, especially KLK5 and
KLK7, act as main players in desquamation through a pH-
dependent protease signaling cascade (Fig. 1).20 KLK7
directly cleaves CDSN and DSC1 but is unable to degrade
DSG1, while KLK5 can.54 During KLK proteolytic activa-
tion cascade, pro-KLK5 is activated by KLK14 and by
KLK5 itself, and the active KLK5 then activates pro-KLK7
and pro-KLK14; thus, KLK5 is believed to be the cascade
initiator.24 Besides KLK5, -7, and -14, it has been reported
that KLK8 is also involved in skin desquamation through a
protease cascade reaction leading to the degradation of
DSG1 and CDSN.29 Recently, KLK6, -13, and -14 have
been found to degrade DSG1 and be inhibited by LEKTI,
suggesting that these KLKs are also potential desquama-
tory enzymes.54 The desquamation process is tightly con-
trolled by the epidermal pH gradient. Skin pH regulates
not only the activity of KLK but also the binding of KLK
to LEKTI fragments.55 At a neutral pH of the SG-SC junc-
tion, KLK is tightly bound to LEKTI fragments, however,
with a decrease in pH (acidic pH of the SC) the dissocia-
tion of KLK from LEKTI becomes more frequent, releas-
ing free KLKs into the outer layer of the SC.55 However, at
the acidic pH of the superficial SC layer, KLKs exhibit
lower activity than at a neutral pH. This bidirectional
regulation of KLKs and their inhibitors by pH is important
to maintain proper skin desquamation.13 In addition to
serine proteases, cystein protease, cathepsin V, and cysta-
tin M/E, an inhibitor of asparaginyl endopeptidase legu-
main (LGMN) and cysteine proteases also controls desqua-
mation.56,57 Cathepsin V has been known to degrade DSG1,
DSC1, and CDSN with a higher proteolytic activity at an
acidic pH, suggesting that cathepsin V is a major player in
desquamation under basal conditions with a normal SC
acidic pH.56 Cystatin M/E regulates desquamation by inhi-
bition of cathepsin V as well as LGMN, which regulates
pH-dependent processing of (pro)-cathepsins. In addition,
cystatin M/E regulates crosslinking of structural proteins
by transglutaminase (TGM) 3 during epidermal differen-
tiation by controlling cathepsin L and LGMN activities.56 A
recent study has shown that the cystatin M/E and cathep-
sin V were expressed to a lesser degree in lesional skin of
AD, suggesting that disturbance of the cystatin M/E-
cathepsin pathway could contribute to abnormal skin
barrier function in AD.58 
Degradation of lipid processing enzyme
The permeability barrier function of the SC is provided by
lipid bilayers and corneocytes. The lamellate structure of SC
intercellular lipids is formed by the delivery of lipid precur-
sors to the SG-SC junction by LBs and the proper process-
ing of these precursors by their extracellular processing
enzymes. It has been demonstrated that serine proteases
have a central role in the formation and maintenance of the
epidermal lipid barrier by degrading the key lipid processing
enzymes required for normal permeability barrier homeos-
tasis and PAR-2-mediated manipulating LB secretion (Fig.
1).7,21 Hachem, et al.21 reported that increased serine protease
activity provoked by sustained SC neutralization with super-
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Fig. 2. Role of PAR-2 in the epidermal permeability barrier homeostasis. LB, lamellar body; PAR-2, protease-activated receptor-2. 
base application in murine skin leads to degradation of both
β-glucocerebrosidase (β-GlcCer’ase) and acid sphingomye-
linase (aSMase) and consequent defect of epidermal barrier
function, which was reversed by coapplied SP inhibitors. In
addition to this direct proteolytic effect, serine proteases
could affect LB secretion via PAR-2 activation.7
Control of antimicrobial function in skin
Antimicrobial peptides (AMPs) are important molecules
that comprise the innate immune defense system of the
skin. Besides their antimicrobial activity, AMPs in skin
have been known to have multiple functions, including
modulation of host imflammatory responses and promo-
tion of wound healing.59 Moreover, previous study has sug-
gested that AMPs are associated with permeability barrier
function by showing a significant delay in permeability
barrier recovery after tape stripping and structural abnor-
malities in LB contents in cathelin-related antimicrobial
peptide (CRAMP), the murine homologue of LL-37,
knockout mice.60 Recently, proteases have been demon-
strated to regulate the antimicrobial activity or inflamma-
tory effect of AMPs through proteolytic degradation of
these peptides. KLK5 and KLK7 were shown to be co-
localized with cathelicidin and to control enzymatic acti-
vation of the cathelicidin precursor (hCAP18) and also to
influence processing into shorter peptides with alternate
biological activity.22 The observation that the epidermal
extracts of SPINK5-deficient mice show increased antimi-
crobial activity as compared with the controls indicates
that the processing of cathelicidin by highly active serine
proteases in SPINK5-deficient mice skin augmented
antimicrobial activity.22 Recent study has demonstrated that
the expression of KLK5 and cathelicidin was up-regulated
in the lesional skin of patients with rosacea with altered
abundance and the processing of cathelicidin peptides
compared to normal individuals.61 It was also suggested
that the high levels of abnormally processed cathelicidins
observed in rosacea patients are a result of a post-transla-
tional processing associated with increased serine protease
activity and that these proteolytically processed forms of
cathelicidin peptides trigger skin inflammation in rocasea.61
PAR-2- mediated function
Permeability barrier homeostasis
The involvement of PAR-2 in epidermal permeability
barrier homeostasis by mediating signaling from serine
proteases in the skin has been recently evidenced.7,11,12 Al-
though controversial, recent studies have shown that PAR-
2 localized in the suprabasal layers of mouse and human
epidermis with high levels of PAR-2 in the stratum gra-
nulosum, suggesting that PAR-2 might act as the primary
sensor of barrier-initiated serine protease activity.7,62,63
Acute barrier disruption leads to an increase in SC pH
from basal levels of 5.0-5.5 toward a more neutral pH,
which, in turn, increases the activity of serine protease,
which has an optimal activity at neutral pH.11,64 This inc-
rease in serine protease activity activates PAR-2 on kera-
tinocytes of SG, resulting in decreased LB secretion and a
consequent decrease in the formation of caveolae and lipid
raft (Fig. 2).7 It was reported that topical PAR-2 agonist pep-
tide significantly delayed barrier recovery and inhibited
LB secretion following acute barrier disruption in murine
skin, whereas PAR-2 knockout mice showed increased LB
secretion and accelerated barrier recovery following acute
disruption as compared to wild-type littermates.7 In addi-
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Fig. 3. PAR-2 and Netherton syndrome. Ela-2, pancreatic elastase-2; KLK, kallikrein; LETKI, lympho-epithelial Kazal-type-related inhibitor; PAR-2,
protease-activated receptor-2; SPINK-5, serine protease inhibitor kazal-type 5; TSLP, thymic stromal lymphopoietin.
tion, inhibition of PAR-2 activation, by topical application
of either serine protease inhibitor or PAR-2 specific anta-
gonist significantly accelerated the barrier recovery rate
after acute barrier disruption.65 These results implicates that
PAR-2 activation might be an important signal for regulat-
ing LB secretion during the repair response after barrier
disruption. While serine protease/PAR-2 signaling negati-
vely affects permeability barrier homeostasis by inhibiting
the restoration of lipid barrier (mortar), it could also act as
a positive regulator in the permeability barrier recovery by
accelerating cornification, which then induces the forma-
tion of corneocytes (bricks) (Fig. 2).11 Recent studies have
demonstrated that proteolytically active allergens, house
dust mites and cockroaches, also activated PAR-2 and
delayed barrier recovery via PAR-2 signal-mediated inhibi-
tion of LB secre-tion.12 By showing the abnormal distribu-
tion of calcium ions after barrier disruption in skin where
allergens had been applied, the authors suggest that PAR-2
signaling-mediated modulation of calcium ions in the skin
could be one of the mechanisms involved in the regulation
of LB secretion by PAR-2.12
Inflammation
The role of PAR-2 in the regulation of inflammation has
been widely investigated. During cutaneous inflammation,
potential endogenous activators of PAR-2, including leuko-
cyte elastase, mast cell tryptase, proteinases of the trypsin-
family produced by keratinocytes (trypsinogen-4), and
proteinases of the fibrinolysis cascade such as factor VII/Xa,
are released; these then activate PAR-2 on keratinocytes,
endothelial cells, inflammatory cells, and dermal sensory
nerves to amplify the inflammation via the up-regulation
of inflammatory mediators.66 It has been demonstrated that
PAR-2 agonist peptide induces intercellular adhesion mole-
cule-1 (ICAM-1) expression in primary human keratino-
cytes via the activation of nuclear factor-kappa B.67 Another
study reported that stimulation of PAR-2 on keratinocytes
increased the secretion of interleukin (IL)-6 and granulo-
cyte-macrophage colony-stimulating factor (GM-CSF).68
In keratinocytes, PAR-2 activation also leads to a secretion
of IL-8/CXCL8, promoting granulocyte and T-cell recruit-
ment.69 The observation that PAR-2 deficient mice show
diminished ear swelling and inflammatory infiltrates in a
model of contact hypersensitivity indicates that PAR-2
mediates inflammation in allergic dermatitis.70 In addition,
PAR-2 has been observed at increased levels in lesional
skin of patients with AD, suggesting that PAR-2 plays a
role in inflammatory dermatosis.15,17 In addition to these
proinflammatory responses, PAR-2 also has been shown
to be involved in the T-helper type 2 (Th2) mediated aller-
gic inflammation. Thymic stromal lymphopoietin (TSLP),
a Th2-associated cytokine produced by inflammatory cells
as well as epithelial cells, is known to induce Th2 cell
recruitment and allergic inflammation via dendritic cell
stimulation in response to allergen challenge, microbial
infections, and inflammation.71 TSLP transgenic mouse has
been shown to develop an AD-like skin disease, which
suggests an important role of TSLP in initiating and per-
petuating Th2 immune responses in AD.72,73 A recent study
reported that SPINK5 knockout mice expressed TSLP in
the epidermis at a higher rate than that of wild-type epider-
mis, and demonstrated that KLK5 directly activates PAR-2,
which in turn induces nuclear factor κB-mediated over-
expression of TSLP. This implies that LEKTI defici-ency-
induced serine protease/PAR-2 activation triggers proin-
flammatory as well as proallergic inflammatory res-ponses
in the development of AD-like phenotype of NS (Fig. 3).74
Pruritus 
Skin nerve fibers are known to have functional PAR-2,
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Fig. 4. Proteases and PAR-2 in the pathogenesis of atopic dermatitis. LETKI, lympho-epithelial Kazal-type-related inhibitor; PAR-2, protease-
activated receptor-2; SCCE, stratum corneum chymotrypsin-like enzyme; SCTE, stratum corneum trypsin-like enzyme; SNP, single nucleotide
polymorphism.
and it has been proposed that PAR-2 plays an important
role in pruritus. During neurogenic inflammation, various
endogenous serine proteases such as tryptase from mast
cells and trypsins from keratinocytes activate PAR-2 on
sensory nerve ending to release calcitonin gene-related pep-
tide (CGRP) and substance P (SP). These neuropeptides
induce vasodilation, edema, and leukocyte recruitment,
resulting in neurogenic inflammation in the local skin lesi-
ons.75 PAR-2 is not only expressed in the peripheral nervous
system but also in the central nervous system, spinal cord
and brain. Therefore, PAR-2 signaling also stimulates the
release of neuropeptides from central nerve endings at the
spinal cord level, thereby activating CGRP receptor and
SP receptor (NK1R) to transmit itch responses to the cen-
tral nervous system.76 In addition, skin exposure to exoge-
nous microbial proteases could also induce itch and inflam-
mation via PAR-2. Recent study reported that the mice that
over-expressed epidermal KLK7 displayed massive itchy
behavior.77 Another study demonstrated that trypsin-induced
scratching behavior in mice was inhibited by a PAR-2
blocking peptide, suggesting the role of serine protease/
PAR-2 signaling in pruritus.78 Moreover, PAR-2 activation
is likely to be involved in pruritus of AD.79 PAR-2 and
trypsin have been observed to be expressed at high rates in
the lesional skin of patients with atopic dermatitis, and
PAR-2 agonist peptides induce pruritus in AD patients.41 In
addition, the fact that KLK5, -7, -8, and -14 are present in
sweat, (sweat being the most common itch-triggering factor
in AD) point to the important role of PAR-2 in pruritus of
AD patients.7,80 PAR-2 is reported to interact synergisti-
cally with transient receptor potential (TRP) vanilloid-type 1
(TRPV1), which belongs to the superfamily of TRP chan-
nels, thereby amplifying itch sensation.81 These findings
suggest that serine protease inhibitors or PAR-2 antago-
nists might be a promising therapeutic tool for the mana-
gement of itching and help break the vicious itch-scratch
cycle in AD.41,75
Genetic abnormalities in the genes encoding 
protease/protease inhibitor
There is increasing evidence that genes related to protease/
protease inhibitor become deregulated in patients with AD,
shifting the balance between proteases and protease inhi-
bitors toward increased protease activity (Fig. 4). It has been
de-monstrated that there is an association between AD and
a four base pair (AACC) insertion in the 3’-untranslated
region of KLK7 gene, which increases the half-life of
KLK7 mRNA and enzymatic activity of KLK7.82 The rare
AACCAACC variant of KLK7 gene showed a more signi-
ficant association with AD as compared to the common
AACC variant. The genetic variant of KLK7 gene was
found to be more significantly relevant in patients who did
not have an elevated IgE level. The enzyme KLK7 plays
an important role in desquamation by cleaving corneodes-
mosomal proteins. In addition, it was reported that transge-
nic mice over-expressing KLK7 presented cutaneous
manifestations similar to chronic AD.83 This implies that
the gain-of-function mutation polymorphism in the KLK7
gene causes a premature breakdown of corneodesmo-
somes, leading to excessive desquamation and impairment
of the epidermal barrier in the development of AD. In
addition to abnormalities in the protease-encoding genes,
several genomic defects in genes encoding members of the
protease inhibitors have been identified in patients with
AD. LEKTI is an inhibitor of multiple serine proteases in
skin and tightly regulates the enzymatic activities of serine
proteases including KLK5, -6, -7, -13, and -14, thereby
controlling epidermal barrier function.31
A premature stop codon mutation in the SPINK5 gene,
which encodes LEKTI, is known to be associated with NS,
a rare ichthyosiform dermatosis characterized by congeni-
tal ichthyosiform erythroderma, severe atopic manifesa-
tions, and hair-shaft abnormality.84 The SPINK5 gene
consists of 33 exons, encoding 15 LEKTI inhibitory do-
mains with selective/specific inhibitory function.85 Previous
study attempting to correlate genotype with phenotype in
Japanese NS patients has demonstrated that the clinical
severity of NS correlates with the residual expression of
LEKTI-1.86 SPINK5-deficient mice have been reported to
show increased proteolytic activities of KLK5 and KLK7
in the epidermis, abnormal degradation of DSG1, and
resultant abnormal corneodesmosome cleavage and
premature desquamation, suggesting that LEKTI is a key
regulator of KLK5 and KLK7 activity and that defective
SC adhesion by epidermal protease hyperactivity is the
primary pathogenic event in NS.87 Recently, ELA2, a novel
epidermal protease, has been identified in human and
mouse skin and conceived as a potential trigger in NS
pathogenesis by misprocessing of filaggrin and lipid.88
Being localized to the keratohyalin granule, ELA2 directly
degrades (pro-) filaggrin and disrupts the lipid lamellae
formation. LEKTI was demonstrated to inhibit ELA2 acti-
vity indirectly, by controlling KLK5-mediated cleavage of
pro-ELA2, and indeed, ELA2 was observed to be hyperac-
tive in the LEKTI-deficient epidermis of NS patients and
SPINK5-deficient mice.88 Transgenic mice over-expres-
sing ELA2 also mimic the clinical features of NS patients
with transient ichthyosiform dermatitis and impaired lipid
barrier, implying that ELA2 is a critical epidermal protease
that regulates epidermal barrier homeostasis, involving the
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pathogenesis of NS. Several studies reported that the poly-
morphisms in the SPINK5 gene are also associated with
AD.84,89 Glu420Lys single-nucleotide polymorphism in the
SPINK5 gene was observed to be associated with AD and
six other SPINK5 gene polymorphisms were also found in
Japanese patients with AD.84,89 In addition, another protease
inhibitor, cystatin A-encoding gene (CSTA gene) poly-
morphism (+344c variant) has been reported to be asso-
ciated with AD.90 Cystatin A is a cysteine protease inhibi-
tor and is known to inhibit the endogenous cathepsins B, -H,
and -L and the exogenous proteases from house dust mites,
such as dermatophagoides pteronyssinus (Der p) 1 and
dermatophagoides farinae (Der f) 1. This +344c variant in
CSTA gene results in the reduced levels of cystatin-A in
the skin surface and sweat, allowing exogenous proteases
to break down the integrity of the SC, which in turn enhances
the penetration of allergens, triggering an aggravation of
AD. These genetic variants in protease and protease inhi-
bitor genes can be combined in some patients with AD,
resulting in a more severe defect in the skin barrier. 
Elevated pH
The skin has a distinct pH gradient across the SC, with a
progressively more acidic pH from the deeper layer to the
outer layer of the SC.91 Studies have demonstrated the ‘acid
mantle’ within the SC plays a critical role in regulating epi-
dermal permeability barrier homeostasis, the epidermal
antimicrobial barrier, and SC integrity/cohesion by regulat-
ing the activity of various enzymes including serine pro-
teases and lipid-processing enzymes.91 Skin pH is known to
be generated by the endogenous processes, including trans-
urocanic acid production from histidine, free fatty acid pro-
duction via secretory phospholipase A (sPLA2), and the
sodium-proton antiporter-1 (NHE-1)-mediated H+ secre-
tion.92 Numerous endogenous factors, such as moisture,
sweat, sebum, anatomic site, genetic predisposition and age
as well as environmental factors, such as soap/detergents,
topical irritant, antibiotics, and cosmetic products, and
occlusive dressings can affect skin pH.93 In the lesions of
patients with AD, the skin pH has been reported to be
significantly elevated.94 The genetically determined barrier
deficiency and various environmental factors are thought
to be associated with the increased skin surface pH in AD
lesions. 
Since Palmer, et al.95 first identified the loss-of-function
mutation in the gene encoding filaggrin (FLG) as a strong
predisposing factor for AD, a number of additional studies
have reported other mutations of FLG genes, including 20
mutations in European populations and 17 in Asian popula-
tions.96 From these reports, it is now conceived that muta-
tions of the FLG gene are the most significant genetic factors
in AD and the resultant genetically determined epidermal
barrier defect is the primary event triggering immunologic
pathogenesis in AD. Filaggrin itself contributes to the epi-
dermal barrier integrity by cross-linking the keratin fila-
ments and the being degraded into a combined pool of highly
hygroscopic amino acids, called the NMF, thereby contri-
buting to the SC hydration. It is also postulated that filag-
grin contributes to the formation of acid mantle within SC
through the generation of urocanic acid via filaggrin-histi-
dine-urocanic acid cascade.97 Therefore, filaggrin deficiency
in AD lesion leads to defects in the formation of cornified
envelope and a decreased ability of maintaining SC hydra-
tion and a concomitant elevation of pH. The elevated pH
enhances the activity of KLK5 and KLK7, which have opti-
mal activity at neutral pH, resulting in the over-degradation
of corneodesmosomes and a decrease in SC integrity and
cohesion. In addition, the abnormally neutral skin pH inhi-
bits the activity of lipid-processing enzymes, including β-
GlcCer’ase, aSMase, and sPLA2, which are essential in
the production of ceramide and free fatty acids and causes
impaired lipid processing and defects in the lipid barrier.
SC acidity is also important in epidermal antimicrobial
barrier function, inhibiting the growth of pathogens. Growth
of Staphylococcus aureus, which colonizes the lesional
skin of AD, is normally inhibited at low skin pH; therefore
the elevated pH in AD lesional skin leads to bacterial growth,
resulting in allergic inflammation and aggravation of AD.94
In addition to these genetic factors, various environmental
factors can increase skin surface pH in AD patients. For
instance, the frequent use of soaps/detergents seems not
only to aggravate AD through directly irritating the skin by
removing skin surface lipids, but also raises skin pH because
most detergents are alkaline; but even at neutral, overuse
of soap and detergent can have a negative effect on epider-
mal barrier function. 
Exogenous proteases  
Various contact allergens and aeroallergens are considered
important factors in the initiation and aggravation of AD.
Proteolytic activity from allergens has been known to play
a role in the pathogenesis of allergic diseases including
allergic rhinitis, asthma, and AD through inducing Th2
allergic inflammation and directly affecting the structure
and function of epidermal barrier, thereby facilitating
further penetration of allergens through the defective skin
barrier.98 House dust mite and cockroach allergens, the
most important environmental factors in the pathogenesis
of AD, have been shown to have proteolytic activity. House
dust mite allergens have been reported to contain several
cysteine and serine proteases. Serine proteases from mite
allergens, Der p 3 and Der p 9, are known to activate PAR-2
on keratinocytes to produce cytokines and contribute to the
pathogenesis of AD, whereas Der p 1 with cystein protease
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activity stimulates inflammation via a PAR-2-independent
mechanism.99 The cockroach allergens, another type of
major aeroallergen, are also reported to activate PAR-2 on
keratinocytes. Jeong, et al.12 reported that the topical appli-
cation of house dust mites and cockroach allergens to bar-
rier-disrupted skin delayed barrier recovery and lamellar
body secretion in murine and human skin via PAR-2 acti-
vation. The topical application of cockroach allergens also
showed an inhibitory effect on the epidermal calcium gra-
dient change after barrier disruption, suggesting that the
negative effects of cockroach allergens on barrier recovery
may be due to the PAR-2 signal-induced epidermal calcium
modulation. Recently, Staphylococcus aureus has also been
reported to produce extracellular V8 protease, which exhi-
bits a similar specificity of glutamate-specific cleavage and
a similar sequence to exfoliative toxins and cause epidermal
permeability barrier dysfunction in the skin of nude mice
by directly degrading DSG1.100 These imply that proteoly-
tically active allergens could break down the skin barrier
via PAR-2-mediated inhibition of lamellar body secretion
or PAR-2-non-mediated mechanisms, including degrada-
tion of corneodesmosomal proteins and lipid processing
enzymes, triggering further allergen penetration through
the disrupted epithelial barrier to aggravate Th2-mediated
inflammation and possibly switch the non-IgE-associated
form of AD (atopiform AD) to the typical IgE-associated
form of AD. Recently, several reports have suggested that
proteolytically active allergens perturb not only the SC per-
meability barrier but also the tight junction (TJ), another
functional barrier of the skin.101-103 The exfoliative toxin-
negative Staphylococcus strains were shown to decrease
the expression of TJ and atypical protein kinase C, a key
player in TJ assembly with decreased transepithelial resis-
tance in the human keratinocyte cell line.101 Previous studies
have reported that house dust mite allergen Der p 1 dis-
rupts intercellular TJ via proteolytic cleavage of TJ adhesion
protein, claudin-1 and occludin in airway epithelial cells.102
Pollens, which are known to be associated with allergic rhini-
tis and conjunctivitis, also contain proteolytic enzymes on
their surface and degrade the TJ proteins of human airway
epithelial cells.103 These findings suggest that proteases deriv-
ed from house dust mite, cockroaches, Staphylococcus aur-
eus, and pollens contribute to the pathogenesis of AD by pro-
pagating the vicious cycle of protease-mediated permeabi-
lity barrier defect and increased allergen penetration (Fig. 4). 
Identification of the important role of PAR-2 in various
AD symptoms, including inflammation, pruritus and skin
barrier impairment, has suggested that PAR-2 antagoni-
zing treatment may be a potential therapeutic strategy for
AD. In addition, the crucial role of mast cells and mast
cell-expressed PAR-2 in various inflammatory diseases
also suggests that PAR-2 antagonizing treatment could be
applied to several chronic inflammatory diseases, such as
asthma,104 rheumatoid arthritis105 and inflammatory bowel
diseases (IBD).106 Theoretically, several approaches could
be used to antagonize PAR-2 activation, including down-
regulation of protease activity, inhibition of PAR-2 expres-
sion using siRNA technology, PAR-2 monoclonal antibody
or PAR-2 specific antagonist; however, at this time, a
practical application of PAR-2 antagonizing treatment has
not yet reported. 
Down-regulation of protease activity to control PAR-2
activation in skin can be achieved by either topical protease
inhibitors or pH controlling agents. We recently reported
that the topical application of serine protease inhibitor (soy-
bean tryptic inhibitor) significantly reduced the pruritus
symptoms in end-stage renal dysfunction patients, where
increased PAR-2 expression in skin was observed. Impro-
vement of skin barrier functions was also observed after
protease inhibitor application.107 While this is a relatively
easier way to control PAR-2 activation, proteases are res-
ponsible not only for PAR-2 activation, but also for other
normal homeostatic processes such as desquamation. As a
result, use of protease inhibitors may have adverse effects
on the skin, which is a major drawback for practical appli-
cation of protease inhibitors for topical use. 
Normal skin surface pH ranges from 5.0 to 5.5, which is
relatively acidic compared to the normal physiologic pH,
and it is well known that pH gradually increases across the
SC. This “acid mantle” is very important for the maintain-
ing skin’s homeostasis, including regulating protease
activity. In AD, increase of skin surface pH is well reco-
gnized and increased proteolytic activity is also observed.
In addition to the PAR-2 activation, increased pH is also
considered responsible for increased susceptibility to se-
condary infections in AD patients. As a result, controlling
skin surface pH within normal acidic range is a very im-
portant therapeutic regimen for AD patients and use of soap
or alkaline detergents is strongly discouraged.
The inhibitory activity of the PAR-2 antibody on itching
behavior in chronic dry skin itch in an animal model has
also been recently reported. Intradermal injection of PAR-
2 antibody significantly reduced spontaneous scratching
behavior, which alludes the important role of PAR-2 in
itching sensation. Further evidence was provided by the in-
creased scratching behavior after PAR-2 activator injec-
tion.108 However, a therapeutic antibody against PAR-2 has
not yet been reported, and practical application of PAR-2
antibody needs to be further developed.
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THERAPEUTIC APPLICATION OF PAR-2
ANTAGONIZING TREATMENT
Among the several approaches for PAR-2 antagonizing
treatment, use of small molecule PAR-2 specific antago-
nist seems to be the most promising method. However,
while several PAR-1 specific antagonists have already been
reported, the lack of a specific, potent PAR-2 antagonist
has hampered more detailed investigation of the role of
PAR-2 in various diseases and its practical application.
Recently, however, a few PAR-2 specific antagonists and
their in vivo and in vitro effects have been reported. ENMD-
1,068 (N1-3-methylbutyryl-N4-6-aminohexanoyl-pipera-
zine) was the first reported PAR-2 specific antagonist, and
its anti-inflammatory activity was evaluated using both in
vivo and ex vivo models. In a carrageenan/kaolin (C/K)-
induced arthritis animal model, intraperitoneal injection of
ENMD-1,068 showed significant inhibition of joint swell-
ing109 and in ex vivo studies using rheumatoid arthritis syno-
vium and cultured synovial fibroblasts, ENMD-1,068 also
showed inhibitory effects on proinflammatory cytokine pro-
duction in a dose-dependent manner.110 In addition, we
have shown that topical application of ENMD-1,068 on
barrier disrupted skin significantly accelerated barrier
recovery rate, which also suggest the potential application
of ENMD-1,068 as a topical agent.12 However, its low po-
tency ranging low millimolar concentration has made it
impractical for therapeutic application. 
More recently, Kanke, et al.111 have reported several pepti-
domimetic compounds as having PAR-2 antagonistic
activities. Among the compounds, it was reported that K-
14585 {N-[1-(2, 6-dichlorophenyl)methyl]-3-(1-pyrroli-
dinylmethyl)-1H-indol-5-yl)aminocarbonyl}-glycine-L-
lysinyl-Lphenylalanyl-N-benzhydrylamide) showed the
most potent antagonist activity against PAR-2 activating
peptide induced cellular responses. Ex vivo responses, such
as rat-isolated aorta relaxation, and in vivo responses, such
as plasma extravasation in the dorsal skin of guinea pigs
and saliva secretion in anaesthetized mice, were also
inhibited by a systemic injection of K-14585. Interestingly,
it was observed that while K-14585 significantly inhibited
the activating peptide-induced PAR-2 activation signaling,
serine protease (trypsin)-induced signaling was affected to
a much lesser extent. It was suggested that there may be
some structural differences between the activating peptide
binding site and tethered ligand binding site; this distinc-
tion need a further investigation. More interestingly, in a
study of K-14585-induced cellular signaling, higher con-
centrations of K-14585 showed agonistic activity, which
still needs further investigation.112 Given these results, prac-
tical therapeutic application of K-14585 is currently not
achievable.
Currently, the authors are investigating a new PAR-2
antagonist. In a series of in vitro and in vivo studies, the new
PAR-2 antagonist, NPS-1577, has shown potential anti-
inflammatory activity as well as skin barrier improving
activity and anti-hyperproliferative activity on the epidermis
(paper in preparation). While detailed investigations related
to the action mechanism are currently being performed,
NPS-1577 could potentially be used as the first practical
PAR-2 antagonist for therapeutic use in the near future.
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